Wanbury Ltd’s board has approved the incorporation of a new subsidiary, Wanbury Skin Health Limited, to expand its presence in the pharmaceutical industry. The board, meeting on June 26, 2026, sanctioned an estimated aggregate capital outlay of ₹4,10,000 for the new entity. This strategic move involves the subscription to 41,000 equity shares with a face value of ₹10 each, giving the parent company an 82% stake in the subsidiary upon incorporation.

The incorporation is subject to necessary approvals from the Registrar of Companies and other relevant regulatory authorities. Wanbury Ltd will subscribe to the shares via cash consideration at face value. The company stated that all investments in the subsidiary would be disclosed to stock exchanges in compliance with SEBI Listing Regulations and the Companies Act, 2013.

In addition to the corporate expansion, the board appointed statutory auditors for the financial year 2026-2027. M/s. Ernst & Young LLP was appointed as the Internal Auditor, while M/s. ABK & Associates was appointed as the Cost Auditor. Both appointments are for a term of one year.

The board meeting commenced at 3:35 p.m. and concluded at 4:15 p.m. on June 26, 2026. The decisions were taken pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Key Approvals

Wanbury Limited has announced the release of a 40.65% equity share pledge held by its promoter group and a reduction in borrowing costs to sub 10% annually, effective July 1, 2026. These moves follow a debt takeover by Axis Finance Limited and Poonawala Fincorp, marking a shift in the company's financial structure and debt obligations.

Promoter Pledge Release

The pledge created on 1,42,03,818 equity shares, representing 40.65% of the company's paid-up equity share capital and 94.51% of the Promoter Group's holding, has been released. These shares were previously encumbered with Investec AIF and Tata Capital Limited. Following this release, only 5.49% of the Promoter Group's holding remains pledged with SBM towards working capital facilities.

Borrowing Cost Reduction

Consequent to the refinancing arrangement, the company's borrowing costs will decrease to sub 10% per annum from July 1, 2026. This reduction from the previous rate of 12.5% per annum is expected to lower the finance cost of the company and support profitability in the periods ahead.